IL6 and cancer: Researchers have also studied whether the systemic IL6 level could be an indicator of BC risk in healthy women, since evidence of non-steroidal anti-inflammatory treatment leading to reduced risk of developing cancer suggested that circulating pro-inflammatory factors such as this cytokine might be linked to a higher predisposition to breast neoplasms [149].